Company Monitoring Page for Eli-Lilly

latest headlines for company on cafepharma

Lilly's tirzepatide clears high bar set by Novo's Wegovy in obesity
Fierce Biotech
Thu, 04/28/22 - 10:53 am
Tags:
Eli Lilly, tirzepatide, obesity, Wegovy, Novo Nordisk
Late-stage pain pipeline refuses to swell
EP Vantage
Tue, 04/26/22 - 10:29 pm
Tags:
painkillers, Vertanical, Teva Pharmaceutical, Regeneron, Ampio Pharmaceuticals, Biogen, Eli Lilly, Vertex Pharmaceuticals, AstraZeneca, Acadia Pharmaceuticals
Does Eli Lilly's Future Depend on its Alzheimer's Drug?
Motley Fool
Sat, 04/23/22 - 04:02 pm
Tags:
Eli Lilly, Alzheimer's disease, donanemab
The next battle in the never-ending war over Aduhelm
Stat
Fri, 04/15/22 - 01:50 pm
Tags:
Biogen, Aduhelm, Medicare, CMS, Eli Lilly, Alzheimer's disease
Australia-based Telix Pharmaceuticals inks oncology deal with Eli Lilly
Bio Spectrum Asia
Mon, 04/11/22 - 10:36 am
Tags:
Telix Pharmaceuticals, Eli Lilly, radiopharmaceuticals, olaratumab, soft tissue sarcoma
Ukraine war, China's COVID lockdown and more could weigh on J&J's early-year performance—and it may not be alone: analysts
Fierce Pharma
Tue, 04/5/22 - 11:53 am
Tags:
JNJ, pandemic, Ukraine, COVID-19, Merck, Pfizer, Eli Lilly
Novo Nordisk snags high-dose Ozempic approval, turning up the heat on Lilly's Trulicity
Fierce Pharma
Wed, 03/30/22 - 11:11 am
Tags:
Novo Nordisk, Ozempic, diabetes, FDA, Eli Lilly, Trulicity
Big pharma’s key second-quarter data
EP Vantage
Tue, 03/29/22 - 10:32 am
Tags:
Roche, tiragolumab, Giredestrant, Sanofi, Eli Lilly, tirzepatide, Novo Nordisk, GSK, Pfizer, RSV
Lilly, after making $1B bet, posts 'compelling' late-phase data on Dupixent rival
Fierce Biotech
Mon, 03/28/22 - 10:20 am
Tags:
Eli Lilly, lebrikizumab, Demira, Sanofi, Regeneron, Dupixent, atopic dermatitis
Data and regulatory roundup: Pfizer’s feat, an ADHD miss, Eli Lilly’s CRL & more
MedCity News
Mon, 03/28/22 - 10:17 am
Tags:
FDA, Pfizer, etrasimod, Argenxy, efgartigimod, Aligos Therapeutics, Vallon Pharmaceuticals, Adderall, ORIC Pharmaceuticals, ORIC-101, Neurana Pharmaceuticals, tolperisone, Eli Lilly, sintilimab
In Expected Decision, FDA Rejects Lilly's Sintilimab in NSCLC
BioSpace
Thu, 03/24/22 - 10:58 am
Tags:
Eli Lilly, sintilimab, FDA, NSCLC
Eli Lilly CEO's pay falls 9% to $21.5M—no thanks to pension declines
Fierce Pharma
Mon, 03/21/22 - 10:11 am
Tags:
Eli Lilly, Pharma CEOs, Dave Ricks, executive pay
Could This Be Eli Lilly's Next Blockbuster Drug?
Motley Fool
Sun, 03/20/22 - 11:01 pm
Tags:
Eli Lilly, mirikizumab, ulcerative colitis
Eli Lilly takes more heat for campaign contributions to election objectors
Fierce Pharma
Fri, 03/18/22 - 10:52 am
Tags:
Eli Lilly, campaign donations, PAC
What now for low-cost PD-(L)1 competition?
EP Vantage
Fri, 03/18/22 - 10:25 am
Tags:
FDA, anti-PD-L1, Innovent, Eli Lilly
Lilly, BI-Partnered Kidney Trial Stopped Early Due to Positive Results
BioSpace
Wed, 03/16/22 - 11:20 pm
Tags:
Eli Lilly, Boehringer Ingelheim, clinical trials, chronic kidney disease, empagliflozin
Novartis, Eli Lilly and AbbVie join growing list of Big Pharmas severing ties with Russia
Endpoints
Tue, 03/15/22 - 11:36 pm
Tags:
Russia, Ukraine, Novartis, Eli Lilly, AbbVie
Erasca, Eli Lilly partner for colorectal cancer therapy trial
Pharmaceutical Business Review
Fri, 03/11/22 - 10:37 am
Tags:
Erasca, Eli Lilly, clinical trials, ERAS-007, colorectal cancer
A trio of amyloid-targeted Alzheimer's drugs will soon see key results, but an analyst predicts only 50-50 odds for one
Endpoints
Wed, 03/9/22 - 11:09 pm
Tags:
Alzheimer's disease, clinical trials, Roche, Eli Lilly, Biogen, donanemab, lecanemab, gantenerumab
As Eli Lilly grows beyond Research Triangle Park, biopharmas big and small are tapping North Carolina's 'limitless' potential
Fierce Pharma
Tue, 03/8/22 - 10:22 am
Tags:
North Carolina, RTP, Eli Lilly, Amgen, Jaguar Gene Therapy, Thermo Fisher, biotech, biotech hubs

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.